J&J Psoriasis Pill In A Tier Of Its Own After Phase III Win

The US healthcare giant says that icotrokinra could provide an “industry-leading combination of significant skin clearance with demonstrated tolerability in a once-daily pill" after succeeding in late-stage trials.

Leadership concept, One leader red sphere leads other boxes
• Source: Shutterstock

Johnson & Johnson is preparing regulatory submissions for icotrokinra, its first-in-class oral therapy for psoriasis, after the drug hit its main goals in two Phase III studies.

Key Takeaways

J&J's interleukin-23 receptor blocker has hit in two Phase III psoriasis trials, with regulatory filings planned.

The once-daily pill could provide strong competition to BMS's TYK2 inhibitor Sotyktu and a head-to-head study is ongoing.

Originator Protagonist Therapeutics is now set to receive $165m in milestone payments in the first quarter of 2025.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

More from Immunological

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.